The global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market size was valued at US$ 234 million in 2024 and is projected to reach US$ 345 million by 2030, at a CAGR of 6.7% during the forecast period 2024-2030.
United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market size was valued at US$ 76 million in 2024 and is projected to reach US$ 109 million by 2030, at a CAGR of 6.2% during the forecast period 2024-2030.
Treatment market for infections caused by Staphylococcus aureus bacteria resistant to vancomycin antibiotics.
Rising concern over antibiotic-resistant infections driving research and development. Increasing focus on novel antibiotics and combination therapies. Growing emphasis on infection prevention and control measures in healthcare settings.
Report Overview
This report provides a deep insight into the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market in any manner.
Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Eli Lily
- Wockhardt Ltd
- Amprologix Ltd
- CrystalGenomics Inc
- Debiopharm International SA
- Destiny Pharma Plc
- Lysimmune BioScience
- Roivant Sciences Ltd
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
Market Segmentation (by Type)
Market Segmentation (by Application)
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
- Overview of the regional outlook of the Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the
major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
1.2 Key Market Segments
1.2.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Type
1.2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Overview
2.1 Global Market Overview
2.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Competitive Landscape
3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Manufacturers (2019-2024)
3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Manufacturers (2019-2024)
3.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Sites, Area Served, Product Type
3.6 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Competitive Situation and Trends
3.6.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Concentration Rate
3.6.2 Global 5 and 10 Largest Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Chain Analysis
4.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2019-2024)
6.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2019-2024)
6.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2019-2024)
7 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Sales by Application (2019-2024)
7.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (M USD) by Application (2019-2024)
7.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate by Application (2019-2024)
8 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Segmentation by Region
8.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region
8.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region
8.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region
8.2 North America
8.2.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Eli Lily
9.1.1 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.1.2 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.1.4 Eli Lily Business Overview
9.1.5 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections SWOT Analysis
9.1.6 Eli Lily Recent Developments
9.2 Wockhardt Ltd
9.2.1 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.2.2 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.2.4 Wockhardt Ltd Business Overview
9.2.5 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections SWOT Analysis
9.2.6 Wockhardt Ltd Recent Developments
9.3 Amprologix Ltd
9.3.1 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.3.2 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.3.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.3.4 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections SWOT Analysis
9.3.5 Amprologix Ltd Business Overview
9.3.6 Amprologix Ltd Recent Developments
9.4 CrystalGenomics Inc
9.4.1 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.4.2 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.4.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.4.4 CrystalGenomics Inc Business Overview
9.4.5 CrystalGenomics Inc Recent Developments
9.5 Debiopharm International SA
9.5.1 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.5.2 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.5.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.5.4 Debiopharm International SA Business Overview
9.5.5 Debiopharm International SA Recent Developments
9.6 Destiny Pharma Plc
9.6.1 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.6.2 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.6.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.6.4 Destiny Pharma Plc Business Overview
9.6.5 Destiny Pharma Plc Recent Developments
9.7 Lysimmune BioScience
9.7.1 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.7.2 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.7.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.7.4 Lysimmune BioScience Business Overview
9.7.5 Lysimmune BioScience Recent Developments
9.8 Roivant Sciences Ltd
9.8.1 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.8.2 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.8.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.8.4 Roivant Sciences Ltd Business Overview
9.8.5 Roivant Sciences Ltd Recent Developments
9.9 TGV-Inhalonix Inc
9.9.1 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.9.2 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.9.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.9.4 TGV-Inhalonix Inc Business Overview
9.9.5 TGV-Inhalonix Inc Recent Developments
9.10 Therapeutic Systems Research Laboratories Inc
9.10.1 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
9.10.2 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
9.10.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Market Performance
9.10.4 Therapeutic Systems Research Laboratories Inc Business Overview
9.10.5 Therapeutic Systems Research Laboratories Inc Recent Developments
10 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast by Region
10.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast
10.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country
10.2.3 Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Region
10.2.4 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type (2025-2030)
11.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type (2025-2030)
11.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Forecast by Application (2025-2030)
11.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) Forecast by Application
11.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Comparison by Region (M USD)
Table 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections as of 2022)
Table 10. Global Market Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Sites and Area Served
Table 12. Manufacturers Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Type
Table 13. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Challenges
Table 22. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (Kilotons)
Table 23. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (M USD)
Table 24. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) by Type (2019-2024)
Table 25. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2019-2024)
Table 26. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (M USD) by Type (2019-2024)
Table 27. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share by Type (2019-2024)
Table 28. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price (USD/Ton) by Type (2019-2024)
Table 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) by Application
Table 30. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
Table 31. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2019-2024)
Table 33. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2019-2024) & (M USD)
Table 34. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2019-2024)
Table 35. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate by Application (2019-2024)
Table 36. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2019-2024)
Table 38. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2019-2024) & (Kilotons)
Table 43. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 44. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 45. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Eli Lily Business Overview
Table 47. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections SWOT Analysis
Table 48. Eli Lily Recent Developments
Table 49. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 50. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 51. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Wockhardt Ltd Business Overview
Table 53. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections SWOT Analysis
Table 54. Wockhardt Ltd Recent Developments
Table 55. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 56. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 57. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections SWOT Analysis
Table 59. Amprologix Ltd Business Overview
Table 60. Amprologix Ltd Recent Developments
Table 61. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 62. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 63. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. CrystalGenomics Inc Business Overview
Table 65. CrystalGenomics Inc Recent Developments
Table 66. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 67. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 68. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Debiopharm International SA Business Overview
Table 70. Debiopharm International SA Recent Developments
Table 71. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 72. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 73. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Destiny Pharma Plc Business Overview
Table 75. Destiny Pharma Plc Recent Developments
Table 76. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 77. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 78. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Lysimmune BioScience Business Overview
Table 80. Lysimmune BioScience Recent Developments
Table 81. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 82. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 83. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Roivant Sciences Ltd Business Overview
Table 85. Roivant Sciences Ltd Recent Developments
Table 86. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 87. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 88. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. TGV-Inhalonix Inc Business Overview
Table 90. TGV-Inhalonix Inc Recent Developments
Table 91. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Basic Information
Table 92. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Overview
Table 93. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Therapeutic Systems Research Laboratories Inc Business Overview
Table 95. Therapeutic Systems Research Laboratories Inc Recent Developments
Table 96. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (M USD), 2019-2030
Figure 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (M USD) (2019-2030)
Figure 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (M USD)
Figure 11. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Manufacturers in 2023
Figure 12. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Manufacturers in 2023
Figure 13. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type
Figure 18. Sales Market Share of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type (2019-2024)
Figure 19. Sales Market Share of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type in 2023
Figure 20. Market Size Share of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type (2019-2024)
Figure 21. Market Size Market Share of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application
Figure 24. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2019-2024)
Figure 25. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application in 2023
Figure 26. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2019-2024)
Figure 27. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application in 2023
Figure 28. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate by Application (2019-2024)
Figure 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2019-2024)
Figure 30. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country in 2023
Figure 32. U.S. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country in 2023
Figure 37. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region in 2023
Figure 44. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (Kilotons)
Figure 50. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country in 2023
Figure 51. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Type (2025-2030)
Figure 65. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Application (2025-2030)
Figure 66. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Application (2025-2030)
